BOZEN, Sud-Tirol, Italy, September 26, 2011 /PRNewswire/ --
Grifols and Health Robotics jointly announced today the expansion of their I.V. Room of the Future partnership to include the unmatched benefits of integration between Genesis Inventory Management System (distributed by Grifols) and Health Robotics' i.v.STATION, i.v.STATION ONCO, and i.v.SOFT.
" During i.v.STATION's due diligence process, which included visits to 5 hospitals in the Boston, Detroit, and Los Angeles already using the robot for patients, we witnessed why i.v.STATION has totally dominated I.V. Robotics since its market introduction in late 2009. The unanimous feedback from Pharmacy Directors at these Academic, Community and Pediatric hospitals alike included i.v.STATION's short deployment cycles to "Live" status, averaging 5 months from purchase date; same-year payback (R.O.I.) by replacing custom manufactured and pre-mix/frozen solutions with just-in-time, centrally filled, robotic I.V. doses; proven sterility, ISO-3 (inside clean rooms)-ISO-5 (outside clean rooms) air quality, and USP 797 compliance" stated Juan Miguel Cana, Grifols USA's General Manager.The integration between the companies' revolutionary I.V. Room products permits the retrieval of I.V. Compounding materials based on actual items stocked within the I.V. Room instead of working through formulary-only lists; reducing i) inefficient and long trips in/out of the I.V. Room; ii) multiple and unnecessary gown-ups; and iii) time-consuming searches for drug vials and I.V. solutions in stand-alone refrigerators. As an additional integration benefit, when Genesis stores final compounded doses, it can automatically create batch orders to i.v.STATION and i.v.SOFT based on par levels to prevent stock-outs and perform inventory turns, resulting in reduced I.V. Room waste. " After evaluating all major carrousel-based Pharmacy Inventory Management Systems in the North American market, Genesis is no doubt the gold standard for the I.V. Room. Its dual chambers [refrigerated and ambient] temperature storage, Class 100K HEPA filtration, and the unique bi-directional interface to i.v.STATION, i.v.SOFT Assist, and i.v.STATION ONCO puts it well above all other legacy carrousel-based inventory management systems. Other legacy Pharmacy Inventory Management systems were developed for Oral Medications and, in my opinion, fit Sterile Products like a square peg in a round hole," stated Gaspar DeViedma, Health Robotics' Executive Vice President . About Health Robotics : Founded in 2006, Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, winning 100% of all worldwide IV Robot's publicly announced purchases over the past 21 months, and providing over 200 hospital installations in 6 continents with robotics-based technology and software automation solutions. Health Robotics' world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for manual compounding], MEDarchiver® [life-critical clinical information system], and TPNstation™ [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com About Grifols : Grifols, with presence in more than 90 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components. The company's class A shares have been listed on the Spanish Stock Exchange (MCE:GRF) since 2006 and have been part of the Ibex-35 since 2008. In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P) and in NASDAQ- United States via ADRs (NASDAQ: GRFS). Grifols is the third company worldwide in plasma protein therapies, in terms of capacity after the recent purchase of Talecris, with a balanced and diversified range of products. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, as a result of on-going investment plans. Grifols is the world leader in plasma collection with 147 plasma donor centers in the United States to ensure a continued and reliable supply of human plasma for the production of plasma therapies. In terms of production capacity (fractionation), Grifols owns and operates several plants in Spain and the United States that allow it to respond to the growing market demand. Grifols' sustained growth will be supported by a strong presence in the United States, Canada and Europe, where upcoming sales are expected to represent 53%, 7% and 26%, respectively.. Grifols Hospital Division focuses on research, development, manufacturing, and marketing non-biological products used in hospitals, clinics, and infusion centers. Grifols' Hospital Division products are designed to increase safety and efficiency in the hospital pharmacy. For more information, please visit: http://www.grifols.com For specific requests, please contact: